Tong Zhang

No. 30 Science Park Road, Zhong Guan Cun Life Science Park
Changping, 102206, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Real-world efficacy and safety of disitamab vedotin (RC48) plus PD-1 inhibitors in advanced urothelial carcinoma: a single-center retrospective study.

Real-world efficacy and safety of disitamab vedotin (RC48) plus PD-1 inhibitors in advanced urothelial carcinoma: a single-center retrospective study.

Journal: Translational andrology and urology

Published: December 09, 2025

Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China.

Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China.

Journal: Cancer control : journal of the Moffitt Cancer Center

Published: June 05, 2025

Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumors.

Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumors.

Journal: Clinical and experimental medicine

Published: February 12, 2025

Grade 3 and above opportunistic pneumonia or drug-induced interstitial lung disease during tyrosine-kinase inhibitor treatment for advanced non-small-cell lung cancer with RET fusion mutations: coexistence of risks and opportunities.

Grade 3 and above opportunistic pneumonia or drug-induced interstitial lung disease during tyrosine-kinase inhibitor treatment for advanced non-small-cell lung cancer with RET fusion mutations: coexistence of risks and opportunities.

Journal: European journal of medical research

Published: February 07, 2025

Systematic pan-cancer analysis identified NCOA4 as an immunological and prognostic biomarker and validated in lung adenocarcinoma.

Systematic pan-cancer analysis identified NCOA4 as an immunological and prognostic biomarker and validated in lung adenocarcinoma.

Journal: Discover oncology

Published: October 14, 2024

Synthetic Polymer Nanoparticles as an Abiotic Artificial Inhibitor of Tyrosinase.

Synthetic Polymer Nanoparticles as an Abiotic Artificial Inhibitor of Tyrosinase.

Journal: Advanced healthcare materials

Published: October 20, 2023

BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models.

BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models.

Journal: Frontiers of medicine

Published: October 14, 2022

Binding of Proteins to Copolymers of Varying Charges and Hydrophobicity: A Molecular Mechanism and Computational Strategies.

Binding of Proteins to Copolymers of Varying Charges and Hydrophobicity: A Molecular Mechanism and Computational Strategies.

Journal: Biomacromolecules

Published: September 27, 2022

An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models.

An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models.

Journal: Frontiers in immunology

Published: December 03, 2021

Abiotic Mimic of Matrix Metalloproteinase-9 Inhibitor against Advanced Metastatic Cancer.

Abiotic Mimic of Matrix Metalloproteinase-9 Inhibitor against Advanced Metastatic Cancer.

Journal: ACS biomaterials science & engineering

Published: June 21, 2021

High-mobility group box 3 (HMGB3) silencing inhibits non-small cell lung cancer development through regulating Wnt/β-catenin pathway.

High-mobility group box 3 (HMGB3) silencing inhibits non-small cell lung cancer development through regulating Wnt/β-catenin pathway.

Journal: Biological chemistry

Published: February 27, 2020

LncRNA MALAT1 Promotes Lung Cancer Proliferation and Gefitinib Resistance by Acting as a miR-200a Sponge.

LncRNA MALAT1 Promotes Lung Cancer Proliferation and Gefitinib Resistance by Acting as a miR-200a Sponge.

Journal: Archivos de bronconeumologia

Published: December 17, 2018

Showing 1-12 of 14

Last Updated: 09/26/2026